Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | TYMS | P04818 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17117799 | 0.98 | LMNA (0.64) | LMNASMN1; SMN2POLBTYMS | |
| SCHEMBL2132784 | 0.98 | LMNA (0.64) | LMNASMN1; SMN2POLBTYMS | |
| SCHEMBL152962 | 0.98 | LMNA (0.64) | LMNASMN1; SMN2POLBTYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL6107 | 0.92 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL21901970 | 0.92 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL17117772 | 0.92 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL973436 | 0.92 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL15189164 | 0.92 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| SCHEMBL24220694 | 0.91 | LMNA (0.65) | LMNASMN1; SMN2POLBTYMS | |
| SCHEMBL19389362 | 0.91 | LMNA (0.68) | LMNASMN1; SMN2POLBTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419893-B2 | Methods and compositions for maximizing the prevention and/or reduction of various maladies and drug side-effects using uridine | TOSK, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2024187069-A1 | ENGINEERING ENTEROBACTERIA TO SITE-SPECIFICALLY ACTIVATE THE ANTICANCER PRODRUG 5-FLUOROCYTOSINE FOR TREATING COLON CANCER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-3538151-B1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INST BIOMEDICAL RES (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117903229-A | Fluorouridine derivatives, application thereof in preparation of anticancer drugs/prodrugs, drugs/prodrugs and preparation method | 中国科学院微生物研究所 | 2024-04-19 | — | — | CN | disclosed |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2024-03-12 | — | — | US | disclosed |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20230051644-A1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2023-02-16 | — | — | US | disclosed |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| CN-110840907-B | Free radical sensitive uracil ProTide prodrug and pharmaceutical application thereof | 南京医科大学 | 2022-11-25 | — | — | CN | disclosed |
| US-11453858-B2 | Human plasma-like medium | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2022-01-27 | — | — | US | disclosed |
| CN-110840907-A | Free radical sensitive uracil ProTide prodrug and pharmaceutical application thereof | 南京医科大学 | 2020-02-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | LMNA 3712/4885SMN1; SMN2 2708/4885POLB 479/4885 |
| US-11559542-B2 | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | LMNA 3671/4885SMN1; SMN2 2657/4885POLB 474/4885 |
| US-20220023330-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2` - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | LMNA 3621/4885SMN1; SMN2 2660/4885POLB 469/4885 |
| US-12419893-B2 | Methods and compositions for maximizing the prevention and/or reduction of various maladies and drug side-effects using uridine | UMPS, UNG, UGDH | LMNA 2375/4885SMN1; SMN2 308/4885POLB 329/4885 |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | LMNA 3653/4885SMN1; SMN2 2652/4885POLB 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.